Literature DB >> 11074538

Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases.

K Okajima1, Y Sakamoto, M Uchiba.   

Abstract

The incidence and clinical manifestations of disseminated intravascular coagulation (DIC) were examined in patients with a range of underlying disorders. Out of 1,882 patients suspected as having DIC, 204 cases were diagnosed as suffering from DIC and included in this study. The underlying disorders experienced by the patients were solid tumors (33.8%), hematologic malignancies (12.7%), aortic aneurysm (10.8%), infections (6.4%), post-operative complications (4.4%), liver disease (2.9%), obstetric disorders (2.5%), and miscellaneous diseases (26.5%). The incidence of DIC was 10.8% out of all patients suspected of having DIC, and the etiologies were 10.9% in solid tumors, 10.1% in hematological malignancies, 20.4% in aortic aneurysm, 12.7% in infections, 15.5% in post-operative complications, 15.8% in liver disease, 3.7% in obstetric disorders, and 9.8% in miscellaneous diseases. The clinical manifestations of DIC patients were varying dependent on their etiologies. Most DIC patients with aortic aneurysm (95.5%) and post-operative complications (88.9%) did not reveal any clinical manifestations. Although all of the patients with obstetric disorders had bleeding, only 20.0% of the patients had organ failure. In contrast, although only 15.4% of the patients with infections had bleeding, 76.9% of these patients had organ failure. Bleeding was observed in 31.9-50.0% of DIC patients with liver disease, hematologic malignancies, and solid tumors. Organ failure was observed in 21.7-33.3% of DIC patients with liver disease, hematological malignancies, and solid tumors. Analysis by measurement of plasma levels of antiplasmin and plasmin-antiplasmin complex suggested that excessive fibrinolysis might contribute to the development of bleeding in these DIC patients. Differences in plasma levels of thrombin-antithrombin complex and cross-linked fibrin degradation products could not account for the differences in the incidence of organ failure in the patients. These findings suggest that the clinical manifestation of DIC varies and might not only be a reflection of microthrombus formation but also a reflection of the other underlying pathomechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074538     DOI: 10.1002/1096-8652(200011)65:3<215::aid-ajh7>3.0.co;2-7

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

Review 1.  Thrombocytopenias: a clinical point of view.

Authors:  Dino Veneri; Massimo Franchini; Federica Randon; Ilaria Nichele; Giovanni Pizzolo; Achille Ambrosetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

2.  Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation.

Authors:  Sadayuki Kawai; Yasuhiro Sakamoto; Yoshikazu Takahashi; Sonoko Ichikawa; Makio Gamoh
Journal:  J Gastrointest Cancer       Date:  2015-12

3.  The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database.

Authors:  Atsuhiko Murata; Kohji Okamoto; Toshihiko Mayumi; Keiji Muramatsu; Shinya Matsuda
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

4.  A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.

Authors:  Hidenori Takahashi; Satoru Ebihara; Tatsuma Okazaki; Masanori Asada; Hidetada Sasaki; Mutsuo Yamaya
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 5.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.

Authors:  Arturo J Martí-Carvajal; Vidhu Anand; Ivan Solà
Journal:  Cochrane Database Syst Rev       Date:  2015-06-24

Review 6.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

7.  Beneficial effect of low-molecular-weight heparin against lipopolysaccharide-induced disseminated intravascular coagulation in rats is abolished by coadministration of tranexamic acid.

Authors:  Hidesaku Asakura; Yoko Sano; Tomotaka Yoshida; Mika Omote; Yasuo Ontachi; Tomoe Mizutani; Masahide Yamazaki; Eriko Morishita; Akiyoshi Takami; Ken-ichi Miyamoto; Shinji Nakao
Journal:  Intensive Care Med       Date:  2004-06-15       Impact factor: 17.440

Review 8.  Childhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases.

Authors:  Ewa Bien; Lucyna Maciejka-Kapuscinska; Maciej Niedzwiecki; Joanna Stefanowicz; Anna Szolkiewicz; Malgorzata Krawczyk; Jadwiga Maldyk; Ewa Izycka-Swieszewska; Beata Tokarska; Anna Balcerska
Journal:  Clin Exp Metastasis       Date:  2010-06-02       Impact factor: 5.150

9.  Significance of decreased plasma D-dimer levels following lipopolysaccharide-induced disseminated intravascular coagulation in rats.

Authors:  Hidesaku Asakura; Yoko Sano; Mika Omote; Tomotaka Yoshida; Yasuo Ontachi; Tomoe Mizutani; Minori Kaneda; Masahide Yamazaki; Eriko Morishita; Akiyoshi Takami; Ken-ichi Miyamoto; Shinji Nakao
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

10.  Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.

Authors:  Atsuo Takashima; Kuniaki Shirao; Yoshinori Hirashima; Daisuke Takahari; Natsuko T Okita; Takako E Nakajima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.